ESSA Pharma Inc. is the first company to enter the clinic with a drug program based on a new mechanism of action targeting the N-terminal domain of androgen receptors in metastatic castration-resistant prostate cancer patients.
ESSA Pharma, founded in 2009 in Vancouver, Canada, went public last year on the NASDAQ capital market after relocating some...








